Mainak Bardhan, Doctoral Researcher at Howard Hughes Medical Institute-University of Miami Miller School of Medicine, shared a post on LinkedIn:
“Happy to be part of this Phase 1 trial led by Dr Ahluwalia Manmeet Ahluwalia, MD, MBA, FASCO which is currently recruiting patients at Miami Cancer Institute, Baptist Health, BAPTIST HEALTH SOUTH FLORIDA FOUNDATION INC to evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab.
It was a writing exercise Ahmad Ozair MD MPH started and happy to see this coming out in BMC Cancer Springer Nature Springer. Thanks to Amy K. Starosciak, Ph.D. for helping in finalizing it.”
Title: Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial
Authors: Zouina Sarfraz, Ahmad Ozair, Mainak Bardhan, Amy K. Starosciak, Dilanis C. Perche, Lydia C. Hodgson, Yazmin Odia, Minesh P. Mehta, Rupesh Kotecha, Michael W. McDermott, Arun Maharaj, Ana Cristina Sandoval Leon, Reshma Mahtani, Manmeet S. Ahluwalia
Read the Full Article on Springer Nature
More posts featuring Mainak Bardhan on OncoDaily.